quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The Most Active Startup Acquirers Of The Past 3 Years Aren’t Always Who You’d Expect

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: The Most Active Startup Acquirers Of The Past 3 Years Aren’t Always Who You’d Expect Date: 2026-03-20 11:00 Source: https://news.crunchbase.com/ma/most-active-startup-acquirers-3-years-crm-openai-snowflake/ <p>Companies that buy a lot of startups don’t always have a lot in common.</p…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The AI sector's appetite for acqui-hires and smaller purchases of earlier-stage startups continues to boost momentum

    60% confidence
  • Snowflake has 19 acquisitions to date

    60% confidence
  • The pace of startup M&A dealmaking remains fairly robust in 2026

    60% confidence
  • OpenAI has bought 16 companies in the past three years

    60% confidence
  • Six companies made six or more known purchases in the past three years

    60% confidence
  • Salesforce, OpenAI and Snowflake are the most prolific acquirers of seed- and venture-backed startups in recent years

    60% confidence
  • Salesforce has purchased at least 91 companies in the past 20 years

    60% confidence
  • 79 companies acquired three or more seed- or venture-backed startups in the past three years

    60% confidence

Data points we hold from this source

Salesforce · total acquisitions91 companies
OpenAI · total acquisitions16 companies
Snowflake Inc. · total acquisitions19 companies
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com